Background Little is known about the outcomes, safety, and response to subsequent
therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab …

Atezolizumab is an anti–PD-L1 immune checkpoint inhibitor recommended for the treatment
of locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing …

Background The impact of pretreatment factors on immune checkpoint inhibition in platinum-
refractory advanced urothelial cancer (aUC) deserves further evaluation. The aim was to …

This is a comment on" Atezolizumab in patients with locally advanced and metastatic
urothelial carcinoma who have progressed following treatment with platinum-based …

Background The primary analysis of IMvigor130 showed a significant progression-free
survival benefit with first-line atezolizumab plus platinum-based chemotherapy (group A) …

Abstract Background The studies IMvigor 210 cohort 2 and IMvigor211 evaluated the
efficacy of atezolizumab in patients with locally advanced or metastatic urothelial cancer …

Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival …

Background Atezolizumab can induce sustained responses in metastatic urothelial
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …

Until recently in the United States, no products were approved for second‐line treatment of
advanced urothelial carcinoma. On May 18, 2016, the US Food and Drug Administration …

Introduction: Until recently, there has been little advancement in the management of invasive
and metastatic urothelial cancer in over 30 years, and outcomes with cisplatin-based …